111Rx Appoints Former BMS Oncology VP Guo Anfeng as Chief Innovation Officer

SHANGHAI, May 6, 2020 /PRNewswire/ -- On May 6, 111, Inc. (NASDAQ: YI), a Nasdaq-listed company and a leading internet healthcare enterprise, announced the appointment of Mr. Guo Anfeng, former Vice President of the Oncology Business Unit at Bristol-Myers Squibb (hereinafter referred to as "BMS"), as Chief Innovation Officer of 111, Inc. He will be fully responsible for the operation and innovation of the company's internet healthcare platform.

Mr. Guo Anfeng has been deeply engaged in the Chinese pharmaceutical market for two decades, having served numerous renowned multinational pharmaceutical companies, including Pfizer, Bayer, AstraZeneca, and Bristol-Myers Squibb (BMS), accumulating extensive experience in sales, marketing, and ecosystem development. Prior to joining 111.com, Mr. Guo served as Vice President of the Oncology Business Unit and Vice President of the Virology Business Unit at BMS, where he established China’s first outstanding immuno-oncology sales team. Under his leadership, the BMS Virology Business Unit achieved a V-shaped recovery, and its immuno-oncology franchise secured a leading market share.

“1Yao.com launchedPharmaceuticals“The channel commercialization platform strategy is enabling an increasing number of pharmaceutical companies to commercialize their innovative drugs nationwide. Currently, this strategy is at a critical stage of development. Mr. Guo Anfeng brings extensive practical experience and a global perspective in the commercialization of specialty drugs, particularly oncology medications. His joining 1 Drug Network will undoubtedly accelerate the company’s growth. His industry reputation, professional network, and rich management experience will enable him to rapidly build a high-execution team and achieve outstanding performance, thereby making more innovative medicines accessible to patients,” stated Yu Gang, Co-founder and Executive Chairman of 1 Drug Network.

When asked why he joined 1 Drug Network, Mr. Guo Anfeng stated that over the past two years, as a guest speaker, he participated in many forums organized by 1 Drug Network and formed connections with Dr. Yu Gang and Mr. Liu Junling. He was deeply attracted by the legendary experiences, philosophies, and vision of the two founders. Meanwhile, as healthcare reform enters deeper waters—from the “4+7” volume-based procurement program to the continuous emergence of innovative drugs—and with internet healthcare rapidly developing under the impetus of the pandemic, greater synergy is expected between internet pharmaceutical companies and traditional enterprises. He expressed strong confidence in the future development of the internet healthcare sector, particularly for 1 Drug Network.

Mr. Guo Anfeng stated：“Leveraging 1 Drug Network’s robust capabilities in internet healthcare and e-commerce, we are committed to buildingInnovative DrugsThe most efficient and execution-driven, as well as the most robust commercialization team in the field, will be built around experts and patients.Innovative DrugsInternet Healthcare Platform, Empowering Doctors and Patients. We welcome young professionals who are eager to learn and passionate about the internet to join our team.”Guo Anfeng stated that he would simultaneously assume full responsibility for the business of Hanhong Pharmaceutical, a wholly-owned subsidiary under 1 Drug Network, focusing on the commercial operation of innovative drugs, particularly oncology drugs, and related consumables and equipment.

Mr. Anfeng Guo graduated from Nanjing Tech University in 2000 with a Bachelor’s degree in Biopharmaceuticals, and obtained an Executive Master of Business Administration (EMBA) degree in International Healthcare from Nanjing University in 2018.

1Drug.com, co-founded by Liu Junling in 2010, is dedicated to making healthcare accessible through technology. It has built an integrated pharmaceutical and healthcare service platform, creating a one-stop closed-loop ecosystem encompassing medical services, pharmaceuticals, and insurance. This approach addresses the inefficiencies and lack of transparency in the pharmaceutical distribution industry while meeting the public’s growing demand for healthcare services. On September 12, 2018, 1Drug.com listed on the NASDAQ, becoming the only internet-based pharmaceutical and healthcare company from China currently listed in the United States.

Previously, in response to the commercialization challenges faced by pharmaceutical companies after launching innovative drugs, 1YaoWang innovatively proposed an omnichannel commercialization platform strategy. Leveraging its integrated online-to-offline pharmaceutical and healthcare platform, 1YaoWang helps pharmaceutical companies reach pharmacies, clinics, private hospitals, and community hospitals beyond large hospitals in first- and second-tier cities and major chain pharmacies, with a particular focus on hospitals and patients in third- to sixth-tier cities, thereby providing complementary value-added services. 1YaoWang’s unique omnichannel model enables pharmaceutical companies’ innovative drugs to efficiently, rapidly, and extensively reach patients in third- to sixth-tier cities.

According to the financial report, as of2019By the end of the year, 1 Drug Network establishedChina's Largestvirtual pharmacy network. In 2019, the company’s pharmacy service network continued to expand, reaching 235,000 pharmacies, accounting for half of the total number of pharmacies nationwide. Currently, the company has established direct-procurement strategic partnerships with more than 188 pharmaceutical manufacturers.